Vericel (NASDAQ:VCEL) issued its earnings results on Monday, March 5th. The biotechnology company reported $0.03 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.13, Morningstar.com reports. The business had revenue of $23.35 million during the quarter. Vericel had a negative net margin of 27.04% and a negative return on equity of 98.77%.
Vericel (VCEL) traded up $0.13 during midday trading on Wednesday, reaching $11.48. 399,136 shares of the company traded hands, compared to its average volume of 1,078,179. The stock has a market capitalization of $404.36, a price-to-earnings ratio of -21.42 and a beta of 3.15. Vericel has a 52-week low of $2.35 and a 52-week high of $12.80. The company has a debt-to-equity ratio of 0.75, a current ratio of 3.86 and a quick ratio of 3.57.
Hedge funds have recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. acquired a new stake in shares of Vericel during the fourth quarter worth approximately $105,000. Bank of Montreal Can acquired a new stake in shares of Vericel during the fourth quarter worth approximately $140,000. Wells Fargo & Company MN grew its position in shares of Vericel by 1,374.2% during the fourth quarter. Wells Fargo & Company MN now owns 30,029 shares of the biotechnology company’s stock worth $163,000 after buying an additional 27,992 shares in the last quarter. Bank of New York Mellon Corp grew its position in shares of Vericel by 13.8% during the second quarter. Bank of New York Mellon Corp now owns 37,202 shares of the biotechnology company’s stock worth $123,000 after buying an additional 4,523 shares in the last quarter. Finally, Citadel Advisors LLC acquired a new position in Vericel in the third quarter worth $235,000. 37.22% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: This piece was reported by BBNS and is the property of of BBNS. If you are accessing this piece on another site, it was illegally stolen and reposted in violation of U.S. and international copyright law. The legal version of this piece can be read at https://baseballnewssource.com/2018/03/14/vericel-vcel-posts-quarterly-earnings-results-beats-expectations-by-0-13-eps/1973681.html.
Vericel Corporation, formerly Aastrom Biosciences, Inc, is a commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. The Company operates through the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases segment.
Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.